News from merrimack pharmaceuticals, inc. A wide array of domestic and global news stories; news topics include politics / government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages, as well.

May 09, 2011, 03:00 ET
Merrimack Pharmaceuticals. (PRNewsFoto/Merrimack Pharmaceuticals, Inc.)

Merrimack Pharmaceuticals Acquires European and Asian Rights to MM-398, nanoliposomal irinotecan

Merrimack Pharmaceuticals, Inc. and PharmaEngine, Inc. (Taipei, Taiwan) today announced the signing of an agreement under which Merrimack has...

Apr 20, 2011, 09:59 ET
Merrimack Pharmaceuticals. (PRNewsFoto/Merrimack Pharmaceuticals, Inc.)

Merrimack Pharmaceuticals Announces that Recruitment is Open in a Phase 1 Combination Study of MM-111 with Multiple Treatment Regimens in HER2 Positive Patients

Merrimack Pharmaceuticals, Inc. announced today that five patients have received therapy in a Phase I clinical study combining MM-111 with...

Apr 05, 2011, 11:08 ET

Phase 1 Data on MM-121 Will Be Presented at the 102nd Annual Meeting of the American Association for Cancer Research (AACR)

Merrimack Pharmaceuticals, Inc. announced today that Phase 1 results on MM-121, one of the five cancer therapeutic agents from the company's novel...

Jan 25, 2011, 03:00 ET
Michael Porter, Ph.D.  (PRNewsFoto/Merrimack Pharmaceuticals, Inc., Stuart Cahill)

Merrimack Pharmaceuticals Announces the Addition of Michael Porter to its Board of Directors

Michael Porter, Ph.D., has joined the board of directors of Merrimack Pharmaceuticals, Inc., a privately held biotechnology company focused on the...

Jan 19, 2011, 07:00 ET

Michael Porter, Janet Woodcock, Peter Senge Among Speakers at Inaugural Innovation in Healthcare Symposium

On February 1, 2011, the Massachusetts Institute of Technology (MIT) Department of Biological Engineering, Center for Biomedical Innovation, and...

Nov 08, 2010, 15:00 ET
Merrimack Pharmaceuticals. (PRNewsFoto/Merrimack Pharmaceuticals, Inc.)

Merrimack Pharmaceuticals Awarded $2.44 Million in Grants Under the Patient Protection and Affordable Care Program

Merrimack Pharmaceuticals was awarded $2.44 million to support research on 10 of its cancer programs through the Qualifying Therapeutic Discovery...

Sep 13, 2010, 11:22 ET
Merrimack Pharmaceuticals. (PRNewsFoto/Merrimack Pharmaceuticals, Inc.)

Merrimack Pharmaceuticals to Present at the 2010 Stifel Nicolaus Healthcare Conference

Merrimack Pharmaceuticals today announced that it will present at the Stifel Nicolaus 2010 Healthcare Conference in Boston. William Sullivan, Vice...

Jul 22, 2010, 07:00 ET

Merrimack Pharmaceuticals and sanofi-aventis Initiate Enrollment in a Phase 2 Combination Study of MM-121 and exemestane in Breast Cancer

Merrimack Pharmaceuticals, Inc. and sanofi-aventis announced today that the first patient has received an initial dose in a Phase 2...

Jun 17, 2010, 16:02 ET

Melissa Kemp, Ph.D., Wins the Council for Systems Biology in Boston (CSB2) Award Sponsored by Merrimack Pharmaceuticals, Inc.

Melissa Kemp, Ph.D., was named the winner of the third annual Council for Systems Biology in Boston (CSB2) Award, sponsored by Merrimack...

Jun 03, 2010, 07:00 ET

Merrimack Pharmaceuticals' MM-111 Phase 1/2 Trial Design to be Presented at the 2010 ASCO Annual Meeting

Merrimack Pharmaceuticals, Inc. announced today that the design of their Phase 1/2 trial investigating the safety and tolerability of MM-111 in...

Jun 01, 2010, 16:51 ET

Merrimack Pharmaceuticals to Present at the Jefferies 2010 Global Life Sciences Conference

Merrimack Pharmaceuticals today announced that it will present at the Jefferies 2010 Global Life Sciences Conference in New York City. Robert...

Apr 30, 2010, 14:34 ET

Merrimack to Present at BIO on the Development of MM-111, a Novel Bispecific ErbB2/ErbB3 Antibody with Potent Anti-Tumor Activity

Merrimack Pharmaceuticals' MM-111 Team Leader Charlotte McDonagh, Ph.D., will discuss the development of this novel, bispecific antibody on...

Apr 17, 2010, 07:00 ET

Merrimack to Present Pre-Clinical Data on MM-121 and MM-111 at the 101st Annual Meeting of the American Association for Cancer Research (AACR)

Merrimack Pharmaceuticals, Inc. announced today that it will present pre-clinical data on MM-121 and MM-111, the two lead candidates in the...

Feb 22, 2010, 07:00 ET

Merrimack Pharmaceuticals Initiates Enrollment in a Phase 1/2 Combination Study of MM-121 and Tarceva(R) in Patients with Non-Small Cell Lung Cancer

Merrimack Pharmaceuticals, Inc. announced today that the first patient has received an initial dose in a Phase 1/2 clinical study combining MM-121...

Oct 01, 2009, 07:00 ET

Sanofi-aventis and Merrimack Pharmaceuticals Enter Into a Worldwide Collaboration and Licensing Agreement on MM-121, an Anti-ErbB3 Monoclonal Antibody

Merrimack Pharmaceuticals, Inc. and sanofi-aventis announced today the signing of an exclusive worldwide licensing agreement for the...

Sep 21, 2009, 08:05 ET

Merrimack Pharmaceuticals Names Clet Niyikiza, Ph.D. Senior Vice President, Development

Merrimack Pharmaceuticals, Inc., announced today that Clet Niyikiza, Ph.D., has joined the company as Senior Vice President, Development. Dr....

Mar 09, 2009, 09:35 ET

Merrimack Pharmaceuticals Promotes Ulrik B. Nielsen, Ph.D. to Chief Scientific Officer and Edward J. Stewart to Senior Vice President of Business Development

Merrimack Pharmaceuticals, Inc., a privately held biotechnology company focused on the discovery and development of novel treatments for cancer and...

Aug 11, 2008, 01:00 ET

Merrimack Pharmaceuticals Initiates Enrollment in a Phase 1 Study of MM-121, an ErbB3 Antagonist

CAMBRIDGE, Mass., Aug. 11 /PRNewswire/ -- Merrimack Pharmaceuticals, Inc. today announced that the first patient has received an initial dose in...

Jun 10, 2008, 01:00 ET

Merrimack Pharmaceuticals Raises $60 Million in Private Financing

CAMBRIDGE, Mass., June 10 /PRNewswire/ -- Merrimack Pharmaceuticals, Inc., a biotechnology company focused on the discovery and development of...

Mar 14, 2008, 01:00 ET

Merrimack Pharmaceuticals Completes Enrollment in a Phase 2 Study of MM-093 in Patients with Rheumatoid Arthritis

CAMBRIDGE, Mass., March 14 /PRNewswire/ -- Merrimack Pharmaceuticals, Inc. today announced that enrollment has been completed in a Phase 2 trial...